Shots:
Novo Nordisk has reported the P-IIIa (PIONEER TEENS) trial assessing oral semaglutide (3, 7 or 14mg, QD) vs PBO, on top of background treatment with metformin, basal insulin, or both, in 132 pts (10-17yrs.) with type 2 diabetes
Trial showed superior HbA1c reduction vs PBO, lowering blood sugar by 0.83% at 26wks., with a…
